valu usd unless otherwis note
controversi creation trim
number ahead
view cardin report result thursday may
manag recent creat small controversi discuss
headwind tailwind relat earn reexamin
put take adjust expect
report result bmo may report earn
market open thursday may project ep
y/i consensu y/i in-lin
consensu note compani recent incit small controversi
manag call discuss headwind tailwind
seem lean toward headwind share trade
two day follow comment trim
ep captur potenti challeng
look ahead estim impli guid could
rang driven organ growth
pharma well medic margin improv half year tax
benefit partial off-set increas invest spend custom
attrit pharmerica transit note impli guidanc
rang like wider manag eventu provid
reflect larg number move piec recent
becom less optimist around growth pharma segment
report volum soft gener deflat persist also
recent discuss continu invest cordi could slow margin
expans
call detail cardin host call thursday may et
dial-in number confer id
anticip investor question revolv around manag thought
headwinds/tailwind face drug wholes particular
vertic consolid healthcar drug price cah progress
integr acquir asset medic segment
maintain sector perform maintain sector perform rate
share trim price target reflect revis
ep estim consider impli upsid exist
target price headlin risk relat neg revis opioid
crisi disrupt forc keep us sidelin
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
cardin health one three larg drug wholesal
unit state believ share like
multipl range-bound investor get visibl
gener drug price bottom oper
earn growth resum compani
pressur last month gener drug price
deflat increas wholesal competit higher-margin
independ custom slowdown brand drug price
increas weigh result expect
backdrop improv next twelv month end
believ investor expect estim
compani core drug distribut segment bottom
could continu disappoint
estim cardin gener
profit core us drug distribut busi sale
gener drug past two year cardin seen
price gener drug deflat high singl digit mid-teen
percentag rate profit dollar contribut fall
slightli lower rate cardin grow profit gener
drug need volum growth new introduct off-set
impact drug price deflat believ
possibl gener deflat continu high singl digit
pace higher thu current environ persist
upsid risk rate includ stabil drug
price environ could caus earn estim
stabil like drive multipl expans close
outperform expect drive posit earn
gener market potenti client loss
wholesal sell side price compress
larger pharmaci custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
year averag forward trade multipl share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep upsid scenario
ep better ep growth could driven
success medic devic strategi increas volum across
brand gener drug de-lever balanc sheet
level gener price deflat forward
multipl repres high end normal trade
rang drug wholes space multipl
like get neg share
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower expect ep could
driven hiccup implement medic devic
strategi wors expect price environ lower
expect brand gener volum forward
multipl like get posit share
exhibit put take
estim guid put takestailwindspharma organ revenu growth specialtymed organ revenu organ growthmed margin organ improvementspati recoveri acquisit full year manufactur win loss agreement end june spend custom surg increas tax rate reduct share repurchasesimpli guid move ep put takesimpact care technolog distribut
price target share equal ep estim use
multipl reflect year averag forward trade multipl share
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
cah medic surgic busi could also outperform expect drive posit
earn surpris downsid risk includ acceler drug price deterior
gener market potenti client loss wholesal sell side
price compress larger pharmaci custom gpo
healthcar servic product compani offer solut health
system pharmaci healthcar provid compani oper
medic segment busi distributor
brand gener drug specialti drug over-the-counter healthcar product
segment also provid specialti pharmaci servic china joint ventur
call red oak sourc sourc gener pharmaceut
medic busi distributor nation brand medic surgic
laboratori product healthcar provid patient home segment addit
provid profession servic healthcar provid
good sold
revenu
impair charg net
litig credit net
revenu
adj profit tax
profit tax
weight average number share
